Current Oncology (Apr 2022)

EGFR Targeting TKI-Related Skin Toxicities in a Patient with Darker Skin: A Case Report

  • Arman Zereshkian,
  • Alia Thawer,
  • David M. Hwang,
  • Susanna Cheng

DOI
https://doi.org/10.3390/curroncol29040205
Journal volume & issue
Vol. 29, no. 4
pp. 2509 – 2515

Abstract

Read online

Epidermal growth factor receptor (EGFR) targeting tyrosine kinase inhibitors (TKIs) can result in significant skin toxicities that may impact patients’ quality of life. While these skin reactions are well documented in patients with lighter skin, there is a paucity of literature and images to guide clinicians in their assessment in patients with darker skin tones. Given that dermatological reactions in patients with darker skin are not well represented, this can result in the undertreatment or mistreatment of these otherwise common toxicities. Herein, we present a case of a female patient with a darker skin tone with metastatic non-small cell lung carcinoma (NSCLC) with EGFR-TKI-related skin toxicity and her clinical course.

Keywords